#EULAR2022 OP0138: BIOBADASER registry: Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior malignancy ⭐️352 pts w prior malignancy in registry, 32 developed a 2nd incident malignancy 27 rate of cancer/1000 patient years. No diff of cancer or mortality b/w Rx @Rheumnow https://t.co/nTuUooBmzV